
U.S. heart valve manufacturer Edwards Lifesciences finds itself at the center of an EU antitrust complaint filed by its Indian competitor, Meril. The complaint alleges anti-competitive practices related to patents, potentially amplifying the scrutiny of EU regulators on Edwards.
Meril, known for its innovative contributions to the medical field, has taken the legal route by lodging a complaint with the European Commission, according to statements provided to Reuters. The clash between the two companies has been long-standing, with battles over heart valve patents echoing in courtrooms across the globe for several years.
Edwards Lifesciences, a prominent player recognized for its transcatheter aortic valve replacement (TAVR) device in heart surgery, has been under regulatory radar since last year when the EU antitrust watchdog raided its premises on suspicions of market power abuse, as per Reuters reports.
Meril’s complaint specifically targets Edwards’ global unilateral pro-innovation policy, which Meril alleges aims to stifle competition by obstructing interactions between doctors and entities labeled as patent copiers by Edwards.
Moreover, Meril has raised concerns over Edwards’ patent practices, citing instances of evergreening and patent thickets. Evergreening, a controversial tactic in the pharmaceutical realm, involves extending patents on products through minor alterations, while patent thickets refer to the practice of securing multiple patents for minor variations on a single invention.
In response to these accusations, Edwards has vehemently denied any wrongdoing, asserting that it has lawfully secured injunctions against Meril’s Myval system in seven countries and the Unified Patent Court for infringement of its SAPIEN valve and accessory patents.
Edwards defended its actions by claiming that it pursued legal action against Meril due to what it perceives as substantial copying of its technology, rather than fair competition and independent innovation. The company emphasized the importance of intellectual property rights in fostering innovation, stating that such protections are indispensable in advancing life-saving therapies that benefit millions of patients worldwide.
Source: Reuters
Featured News
Activist Groups File Lawsuit Against X in Germany
Feb 5, 2025 by
CPI
EU Regulators to Rule on AMD’s $4.9 Billion ZT Systems Buy Soon
Feb 5, 2025 by
CPI
Tech Titans and World Leaders Gather in Paris for AI Strategy Talks
Feb 5, 2025 by
CPI
Trump Administration Overhauls Justice Department Under Acting Deputy AG Emil Bove
Feb 5, 2025 by
CPI
Judge Signals Parts of Elon Musk’s Lawsuit Against OpenAI Could Go to Trial
Feb 5, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Criminal Enforcement
Jan 23, 2025 by
CPI
The Antitrust Division’s Recent Work to Combat International Cartels
Jan 23, 2025 by
Emma Burnham & Benjamin Christenson
Information Sharing: The New Frontier of U.S. Antitrust Enforcement
Jan 23, 2025 by
Brian P. Quinn, Casey Kovarik & Michael Tubach
The Key Role of Guidelines on Exchanges of Information Among Competitors and the Divergent Transatlantic Paths
Jan 23, 2025 by
Rosa Abrantes-Metz & Albert Metz
Leniency, Whistleblowers, and Compliance
Jan 23, 2025 by
Richard Powers, Tara O’Malley & Cory Gordon